BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 21498159)

  • 21. Experience from the German pegvisomant observational study.
    Strasburger CJ; Buchfelder M; Droste M; Mann K; Stalla GK; Saller B;
    Horm Res; 2007; 68 Suppl 5():70-3. PubMed ID: 18174713
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pegvisomant: a novel pharmacotherapy for the treatment of acromegaly.
    Paisley AN; Trainer P; Drake W
    Expert Opin Biol Ther; 2004 Mar; 4(3):421-5. PubMed ID: 15006735
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Growth hormone receptor antagonists.
    van der Lely AJ; Kopchick JJ
    Neuroendocrinology; 2006; 83(3-4):264-8. PubMed ID: 17047392
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term effects of pegvisomant in patients with acromegaly.
    Hodish I; Barkan A
    Nat Clin Pract Endocrinol Metab; 2008 Jun; 4(6):324-32. PubMed ID: 18431372
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnosis and treatment of pituitary adenomas.
    Chanson P; Salenave S
    Minerva Endocrinol; 2004 Dec; 29(4):241-75. PubMed ID: 15765032
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The place of pegvisomant in the management of acromegaly.
    Parkinson C; Trainer PJ
    Expert Opin Investig Drugs; 2001 Sep; 10(9):1725-35. PubMed ID: 11772281
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Optimization of the medical treatment for acromegaly].
    Díez JJ; Iglesias P
    Med Clin (Barc); 2013 Apr; 140(8):360-5. PubMed ID: 23103101
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful treatment of resistant acromegaly with a growth hormone receptor antagonist.
    Drake WM; Parkinson C; Akker SA; Monson JP; Besser GM; Trainer PJ
    Eur J Endocrinol; 2001 Oct; 145(4):451-6. PubMed ID: 11581004
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
    Colao A; Pivonello R; Auriemma RS; De Martino MC; Bidlingmaier M; Briganti F; Tortora F; Burman P; Kourides IA; Strasburger CJ; Lombardi G
    Eur J Endocrinol; 2006 Mar; 154(3):467-77. PubMed ID: 16498061
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ACROSTUDY: the first 5 years.
    Trainer PJ
    Eur J Endocrinol; 2009 Nov; 161 Suppl 1():S19-24. PubMed ID: 19684052
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of pegvisomant in the treatment of acromegaly.
    Roelfsema F; Biermasz NR; Pereira AM; Romijn JA
    Expert Opin Biol Ther; 2008 May; 8(5):691-704. PubMed ID: 18407771
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs.
    Herman-Bonert VS; Zib K; Scarlett JA; Melmed S
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2958-61. PubMed ID: 10946911
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Akromegaly and pharmacotherapy].
    Šiprová H; Souček M
    Vnitr Lek; 2015 Feb; 61(2):157-60. PubMed ID: 25813261
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pegvisomant in the treatment of acromegaly.
    Parkinson C; Scarlett JA; Trainer PJ
    Adv Drug Deliv Rev; 2003 Sep; 55(10):1303-14. PubMed ID: 14499709
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Review of current and emerging treatment options in acromegaly.
    Muhammad A; van der Lely AJ; Neggers SJ
    Neth J Med; 2015 Oct; 73(8):362-7. PubMed ID: 26478545
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Newer options in the management of acromegaly.
    Burt MG; Ho KK
    Intern Med J; 2006 Jul; 36(7):437-44. PubMed ID: 16780450
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of pituitary tumors: pegvisomant.
    Paisley AN; Drake WM
    Endocrine; 2005 Oct; 28(1):111-4. PubMed ID: 16311417
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination treatment with somatostatin analogues and pegvisomant in acromegaly.
    Neggers SJ; van der Lely AJ
    Growth Horm IGF Res; 2011 Jun; 21(3):129-33. PubMed ID: 21498099
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modulation of cortisol metabolism by the growth hormone receptor antagonist pegvisomant in patients with acromegaly.
    Trainer PJ; Drake WM; Perry LA; Taylor NF; Besser GM; Monson JP
    J Clin Endocrinol Metab; 2001 Jul; 86(7):2989-92. PubMed ID: 11443156
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pegvisomant treatment in patients with acromegaly in clinical practice: The French ACROSTUDY.
    Chanson P; Brue T; Delemer B; Caron P; Borson-Chazot F; Zouater H;
    Ann Endocrinol (Paris); 2015 Dec; 76(6):664-70. PubMed ID: 26596374
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.